Handelsbanken Fonder
NMRA icon

Handelsbanken Fonder’s Neumora Therapeutics NMRA Stock Holding History

Handelsbanken Fonder’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-21,700
Closed -$22K – 1550
2025
Q1 		$22K Hold
21,700
– – ﹤0.01% 1526
2024
Q4 		$230K Sell
21,700
-4,900
-18% -$58.7K ﹤0.01% 1501
2024
Q3 		$351K Buy
26,600
+6,900
+35% +$80.5K ﹤0.01% 1369
2024
Q2 		$194K Buy
+19,700
New +$204K ﹤0.01% 1487

Other funds holding NMRA

SoftBank Group
SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
LC
Lunate Capital Al Maryah Island, Abu Dhabi, United Arab Emirates $196M AUM 84.21% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Handelsbanken Fonder's NMRA Position: Q2 2025 in Review

Handelsbanken Fonder sold out of Neumora Therapeutics (NMRA) in Q2 2025, closing a stake of 21,700 shares — an estimated $22K sold.

Handelsbanken Fonder first reported a position in NMRA in Q2 2024 and held it in 4 quarters. The position peaked at $351K in Q3 2024. 98 funds tracked by Wall St. Rank hold NMRA as of Q2 2025.

  • Handelsbanken Fonder reported no remaining Neumora Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Handelsbanken Fonder sold 21,700 Neumora Therapeutics shares in Q2 2025, an estimated $22K.
  • Handelsbanken Fonder first reported a position in Neumora Therapeutics in Q2 2024 and held it in 4 quarters.
  • Handelsbanken Fonder's Neumora Therapeutics position peaked at $351K in Q3 2024.
  • 98 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2025.

Based on Handelsbanken Fonder's 13F filing for Q2 2025, filed 12 Aug 2025.